Company news
bioAffinity Technologies, Inc. news in 2025
bioAffinity Technologies, Inc.'s news releases, calls and decks from 2025, newest first.
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
December 3, 2025
BioAffinity Technologies Reports Third Quarter 2025 Financial Results
November 17, 2025
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
November 14, 2025
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
November 5, 2025
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
October 28, 2025
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
October 20, 2025
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
October 16, 2025
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
October 15, 2025
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
October 9, 2025
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
October 8, 2025
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
October 7, 2025
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
September 30, 2025
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
September 29, 2025
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
September 26, 2025
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
September 17, 2025
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
September 9, 2025
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
September 3, 2025
bioAffinity Technologies Appoints New Members to Board of Directors
August 18, 2025
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
August 14, 2025
bioAffinity Technologies Reports Second Quarter 2025 Results
August 14, 2025
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
August 13, 2025
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
August 13, 2025
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
July 29, 2025
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
July 23, 2025
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
July 22, 2025
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
July 15, 2025
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
July 9, 2025
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
June 26, 2025
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
June 24, 2025
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
June 11, 2025
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
June 3, 2025
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
May 28, 2025
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
May 20, 2025
bioAffinity Technologies Reports First Quarter 2025 Results
May 15, 2025
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
May 8, 2025
bioAffinity Technologies Announces Closing of $3.25 Million Offering
May 7, 2025
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
May 6, 2025
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
April 17, 2025
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
March 31, 2025
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
March 26, 2025
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
March 19, 2025
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
March 13, 2025
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
March 6, 2025
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
February 26, 2025
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
February 25, 2025
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
January 21, 2025
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
January 12, 2025
Decks in 2025
- H.C. Wainwright Annual Global Investment Conference 2025
Conference · 18 slides · Sep 5, 2025